middle.news
Immutep Secures A$4.6M French R&D Boost for Immunotherapy Trials
9:36am on Monday 3rd of November, 2025 AEDT
•
Biotechnology
Read Story
Immutep Secures A$4.6M French R&D Boost for Immunotherapy Trials
9:36am on Monday 3rd of November, 2025 AEDT
Key Points
A$4.6 million received from French Crédit d’Impôt Recherche (CIR) scheme
Funds relate to 2024 R&D activities conducted in France
Supports global clinical development of eftilagimod alfa and IMP761
Immutep also eligible for Australian R&D tax incentives
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE